A composition comprising: (i) isolated cells having enhanced survival and/or proliferation, wherein the isolated cells having enhanced survival and/or proliferation are prepared by: (a) obtaining a population of cells comprising stem cells, induced stem cells, pluripotent stem cells, progenitor cells, differentiated cells, beta cells or fibroblasts; and (b) contacting the population of cells with an amount of a compound sufficient to improve survival of the cells by at least 2-fold compared to the absence of the compound, wherein the compound has the formula: wherein, R 20 is substituted C 1-6 alkyl or unsubstituted C 3-8 cycloalkyl, wherein the substituted C 1-6 alkyl is substituted with C 3-8 cycloalkyl; R 28 is -OR 40 ; and R 40 is hydrogen or unsubstituted C 1-10 alkyl; or a racemate, diastereomer, tautomer, or a geometric isomer thereof, or a pharmaceutically acceptable salt thereof, and (ii) ingredients selected from the group consisting of aqueous solutions, non-aqueous solutions, isotonic sterile solutions, antioxidants, buffers, bacteriostats, solutes that render the formulation isotonic, aqueous sterile suspensions, non-aqueous sterile suspensions, suspending agents, solubilizers, thickening agents, stabilizers, and/or preservatives. (i) isolated cells having enhanced survival and/or proliferation, wherein the isolated cells having enhanced survival and/or proliferation are prepared by: (a) obtaining a population of cells comprising stem cells, induced stem cells, pluripotent stem cells, progenitor cells, differentiated cells, beta cells or fibroblasts; and (b) contacting the population of cells with an amount of a compound sufficient to improve survival of the cells by at least 2-fold compared to the absence of the compound, wherein the compound has the formula: wherein, R 20 is substituted C 1-6 alkyl or unsubstituted C 3-8 cycloalkyl, wherein the substituted C 1-6 alkyl is substituted with C 3-8 cycloalkyl; R 28 is -OR 40 ; and R 40 is hydrogen or unsubstituted C 1-10 alkyl; or a racemate, diastereomer, tautomer, or a geometric isomer thereof, or a pharmaceutically acceptable salt thereof, and (a) obtaining a population of cells comprising stem cells, induced stem cells, pluripotent stem cells, progenitor cells, differentiated cells, beta cells or fibroblasts; and (b) contacting the population of cells with an amount of a compound sufficient to improve survival of the cells by at least 2-fold compared to the absence of the compound, wherein the compound has the formula: wherein, R 20 is substituted C 1-6 alkyl or unsubstituted C 3-8 cycloalkyl, wherein the substituted C 1-6 alkyl is substituted with C 3-8 cycloalkyl; R 28 is -OR 40 ; and R 40 is hydrogen or unsubstituted C 1-10 alkyl; or a racemate, diastereomer, tautomer, or a geometric isomer thereof, or a pharmaceutically acceptable salt thereof, and R 20 is substituted C 1-6 alkyl or unsubstituted C 3-8 cycloalkyl, wherein the substituted C 1-6 alkyl is substituted with C 3-8 cycloalkyl; R 28 is -OR 40 ; and R 40 is hydrogen or unsubstituted C 1-10 alkyl; or a racemate, diastereomer, tautomer, or a geometric isomer thereof, or a pharmaceutically acceptable salt thereof, and (ii) ingredients selected from the group consisting of aqueous solutions, non-aqueous solutions, isotonic sterile solutions, antioxidants, buffers, bacteriostats, solutes that render the formulation isotonic, aqueous sterile suspensions, non-aqueous sterile suspensions, suspending agents, solubilizers, thickening agents, stabilizers, and/or preservatives. <EOS>